Tuberculosis, Multidrug-Resistant clinical trials

The registry lists 132 studies for Tuberculosis, Multidrug-Resistant across more than 10 countries. 25 are recruiting or about to start. 88 of them are mainly about Tuberculosis, Multidrug-Resistant (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10. Counting its narrower condition Extensively Drug-Resistant Tuberculosis too: 133 studies, 25 open.

Get an email when these change. Save the Tuberculosis, Multidrug-Resistant studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 78
Recruiting: 20
Status unknown: 15
Terminated: 7
Not yet recruiting: 5
Active, not recruiting: 4

Phase

Phase 2: 33
Phase 3: 32
Phase 4: 9
Phase 1: 8

Where

South Africa: 46
China: 26
Peru: 19
Philippines: 16
Georgia: 13
India: 11

Who runs them

Global Alliance for TB Drug Development (9) · Otsuka Pharmaceutical Development & Commercialization, Inc. (7) · Huashan Hospital (7) · National Institute of Allergy and Infectious Diseases (NIAID) (6) · Medecins Sans Frontieres, Netherlands (5) · Foundation for Innovative New Diagnostics, Switzerland (5) · Beijing Chest Hospital (5) · Boston University (4)

What is being tested here

Drugs under test in Tuberculosis, Multidrug-Resistant studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Bedaquiline	3	12	20
Linezolid	2	7	15
Moxifloxacin	2	7	8
Pretomanid	1	7	10
Pyrazinamide	1	3	8
Quabodepistat	1	1	1
Sudapyridine	1	1	1
Tedizolid phosphate	1	0	1
Tedizolid	1	0	1
Amikacin	1	0	1

Coming up

10phase 3 studies under way

10studies finish main data collection within a year3 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 10, phase 3 first

Nov 2026Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients · Phase 3 · National Institute of Allergy and Infectious Diseases (NIAID)
Dec 2026Innovating(IN) Shorter(S), All- Oral, Precised(P), Individualized(I) Treatment Regimen(RE) for Rifampicin Resistant Tuberculosis(INSPIRE-TB) · Phase 3 · Huashan Hospital
Feb 2027Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese Cohort · Phase 3 · Huashan Hospital
Nov 2026Molecular Epidemiology, Strains Genotyping of Multi-drug Resistant Tuberculosis Circulating in Central Africa Region · Centre de Recherche Médicale de Lambaréné
Jan 2027Pragmatic Use of Next-generation Sequencing for Management of Drug-resistant Tuberculosis · University of California, San Francisco
Feb 2027Acetohydroxamic Acid Combined With a Short-Course Regimen for MDR-TB (AHA-PLUS) · Shanghai Pulmonary Hospital, Shanghai, China
Apr 2027An Adaptive Randomized Controlled Trial · Columbia University
May 2027Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine to Treat MDR-TB · Boston University
Jun 2027Bioneer Q-RFIA Clinical Evaluation · Foundation for Innovative New Diagnostics, Switzerland
Oct 2027Linezolid Tolerance During the BPaL Regimen With Dosage Personalization Based on Therapeutic Drug Monitoring (TDM) During Multidrug-Resistant Tuberculosis Treatment · Marco Schiuma

Who these studies take

Of the 20 Tuberculosis, Multidrug-Resistant studies recruiting now, 12 (60%) set no upper age limit and 7 (35%) stop at 75 or younger. 9 (45%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 2 (10%) take healthy volunteers.

Recruiting studies that take each age, of 20
Age	Women	Men
10	5 (25%)	5 (25%)
18	19 (95%)	19 (95%)
30	20 (100%)	20 (100%)
40	20 (100%)	20 (100%)
50	20 (100%)	20 (100%)
65	19 (95%)	19 (95%)
75	15 (75%)	15 (75%)
85	13 (65%)	13 (65%)

Across all 132 studies, recruiting or not: 31% stop at 75 or younger and 20% at 65; 34% take children; 0% are for women only and 1% for men only; 11% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Tuberculosis, Multidrug-Resistant studies take

Of 19 observational studies under Tuberculosis, Multidrug-Resistant, half reached primary completion within 53 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Observational	53 mo32–90 · 19 studies	—	—

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 13, 2026.

Started recruiting1

Molecular Epidemiology, Strains Genotyping of Multi-drug Resistant Tuberculosis Circulating in Central Africa RegionOct 29, 2026NCT07017803

Studies

Recruiting first, then most recently updated. Showing 50 of 132. Browse all 132 → or search them.